Lianjun Shen

3.9k total citations · 1 hit paper
49 papers, 2.8k citations indexed

About

Lianjun Shen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Lianjun Shen has authored 49 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 24 papers in Immunology and 16 papers in Molecular Biology. Recurrent topics in Lianjun Shen's work include CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (11 papers) and T-cell and B-cell Immunology (10 papers). Lianjun Shen is often cited by papers focused on CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (11 papers) and T-cell and B-cell Immunology (10 papers). Lianjun Shen collaborates with scholars based in China, United States and Canada. Lianjun Shen's co-authors include Kenneth L. Rock, Weidong Han, Marianne Boes, Luis J. Sigal, Yongliang Zhang, Yupeng Wang, Feng Shao, Ya Su, Da Li and Lin Shen and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Lianjun Shen

43 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells

2020 940 citations Huabin He, Xuyan Shi et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lianjun Shen China	17	1.6k	1.4k	750	264	211	49	2.8k
Elisabeth Naschberger Germany	32	1.5k 0.9×	1.3k 0.9×	825 1.1×	361 1.4×	264 1.3×	90	3.2k
Cristiana Guiducci United States	28	4.6k 2.9×	1.5k 1.0×	1.3k 1.7×	321 1.2×	429 2.0×	45	5.7k
Vijay Bhoj United States	17	1.3k 0.8×	916 0.6×	2.0k 2.6×	278 1.1×	149 0.7×	39	3.4k
Timothy Kuo United States	14	1.8k 1.1×	741 0.5×	484 0.6×	316 1.2×	104 0.5×	19	3.0k
Hans de Haard Belgium	32	1.1k 0.7×	1.3k 0.9×	622 0.8×	145 0.5×	226 1.1×	79	3.3k
Jeff D. Colbert United States	18	944 0.6×	804 0.6×	526 0.7×	167 0.6×	91 0.4×	20	1.8k
Anke Peters Germany	12	1.3k 0.8×	1.2k 0.8×	408 0.5×	317 1.2×	92 0.4×	23	2.5k
Josef Cihak Germany	23	1.9k 1.2×	900 0.6×	663 0.9×	293 1.1×	161 0.8×	44	3.1k
Daniele Sblattero Italy	35	767 0.5×	1.3k 0.9×	198 0.3×	802 3.0×	241 1.1×	127	3.8k
Martyn K. Robinson United Kingdom	26	795 0.5×	1.0k 0.7×	407 0.5×	172 0.7×	78 0.4×	46	2.6k

Countries citing papers authored by Lianjun Shen

Since Specialization

Citations

This map shows the geographic impact of Lianjun Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lianjun Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lianjun Shen more than expected).

Fields of papers citing papers by Lianjun Shen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lianjun Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lianjun Shen. The network helps show where Lianjun Shen may publish in the future.

Co-authorship network of co-authors of Lianjun Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Lianjun Shen. A scholar is included among the top collaborators of Lianjun Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lianjun Shen. Lianjun Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Mingming, Shan Fu, Guoqing Wei, et al.. (2025). One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus. Blood. 146(Supplement 1). 2384–2384.

Du, Juan, Jing Lu, Haiyan He, et al.. (2024). Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients. Blood. 144(Supplement 1). 2072–2072.

Lu, Jing, Jia Liu, Jin Liu, et al.. (2024). B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma. JAMA Oncology. 10(9). 1259–1259. 10 indexed citations

Yin, Wenjie, Tao Wang, Di Wu, et al.. (2023). 248 SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanced efficacy against solid tumors. SHILAP Revista de lepidopterología. A287–A287.

Luo, Yi, Lei Gao, Jia Liu, et al.. (2023). Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. EClinicalMedicine. 67. 102377–102377. 9 indexed citations

Chen, Xinfeng, Ping Yu, Ling Li, et al.. (2023). CD19/BCMA Dual-Targeting Fastcar-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: An Update. Blood. 142(Supplement 1). 6847–6847. 1 indexed citations

Yang, Junfang, Jiaping He, Xian Zhang, et al.. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer Journal. 12(7). 104–104. 69 indexed citations

Wang, Haopeng, et al.. (2021). Exploiting T cell signaling to optimize engineered T cell therapies. Trends in cancer. 8(2). 123–134. 21 indexed citations

He, Huabin, Xuyan Shi, Yupeng Wang, et al.. (2020). Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 368(6494). 940 indexed citations breakdown →

10.

Zhang, Hua, Lei Gao, Li Liu, et al.. (2019). A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3147–3147. 43 indexed citations

11.

Zhang, Cheng, Jiaping He, Li Liu, et al.. (2019). CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside. Blood. 134(Supplement_1). 1340–1340. 13 indexed citations

12.

Cid, Natasha Del, et al.. (2012). Assessment of Roles for Calreticulin in the Cross-Presentation of Soluble and Bead-Associated Antigens. PLoS ONE. 7(7). e41727–e41727. 4 indexed citations

13.

Zhao, Hang, Shaw‐Woei Leu, Liyun Shi, et al.. (2010). TLR4 Is a Negative Regulator in Noninfectious Lung Inflammation. The Journal of Immunology. 184(9). 5308–5314. 41 indexed citations

14.

Shen, Lianjun, et al.. (2007). CD40-CD40 Ligand Interaction between Dendritic Cells and CD8+ T Cells Is Needed to Stimulate Maximal T Cell Responses in the Absence of CD4+ T Cell Help. The Journal of Immunology. 178(5). 2844–2852. 79 indexed citations

15.

Shen, Lianjun & Kenneth L. Rock. (2005). Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Current Opinion in Immunology. 18(1). 85–91. 128 indexed citations

16.

Shen, Lianjun & Kenneth L. Rock. (2004). Cellular protein is the source of cross-priming antigen in vivo. Proceedings of the National Academy of Sciences. 101(9). 3035–3040. 148 indexed citations

17.

Shen, Lianjun, Luis J. Sigal, Marianne Boes, & Kenneth L. Rock. (2004). Important Role of Cathepsin S in Generating Peptides for TAP-Independent MHC Class I Crosspresentation In Vivo. Immunity. 21(2). 155–165. 297 indexed citations

18.

Shen, Lianjun, et al.. (1996). Major histocompatibility complex class I‐dependent cell binding to isolated Ly‐49A: evidence for high‐avidity interaction. European Journal of Immunology. 26(12). 3219–3223. 12 indexed citations

19.

Shen, Lianjun & Kevin P. Kane. (1995). Differential ability of isolated H-2 Kb subsets to serve as TCR ligands for allo-specific CTL clones: potential role for N-linked glycosylation.. The Journal of Experimental Medicine. 181(5). 1773–1783. 13 indexed citations

20.

Petroni, Katia, Lianjun Shen, & Paul M. Guyre. (1988). Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids.. The Journal of Immunology. 140(10). 3467–3472. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact